OOIR: Observatory of International Research

Papers

(The H4-Index of Value in Health is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	238
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force	237
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiativ	67
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis	63
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group	63
Managed Entry Agreements: Policy Analysis From the European Perspective	61
Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force	61
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs	59
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group	58
Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary	57
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?	53
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report	50
Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review	46
The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results	44
Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis	43
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach	43
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies	42
Distributional Cost-Effectiveness Analysis Comes of Age	41
Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review	40
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review	40
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis	39
Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis	39
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group	37
Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations	36
Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods	36

Preferences for e-Mental Health Interventions in Germany: A Discrete Choice Experiment	34
Using Virtual Reality Exposure Therapy in Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	34
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials	33
Computing PROPr Utility Scores for PROMIS® Profile Instruments	33
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review	32
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom	32
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge	31
Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review	31
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling	31